MM-II OSTEOARTHRITIS DRUG PIPELINE MARKET INSIGHTS AND FORECASTS UPTO 2032
KEY INSIGHTS MM-II is a new non-opioid intra-articular injection designed to alleviate knee pain in patients with osteoarthritis. This treatment utilizes the unique characteristics of proprietary ... もっと見る
SummaryKEY INSIGHTSMM-II is a new non-opioid intra-articular injection designed to alleviate knee pain in patients with osteoarthritis. This treatment utilizes the unique characteristics of proprietary multilamellar liposomes alongside an innovative mechanism of action to deliver long-lasting symptomatic relief. Extensive pre-clinical research has confirmed the safety and lubricating effects of MM-II, which help to minimize joint friction and cartilage wear. Additionally, a first-in-human study has shown that MM-II is well-tolerated and effective in reducing knee pain for osteoarthritis patients. This drug is developed by Moebius Medical. Moebius Medical is a clinical-stage biotech company that specializes in the development of innovative medical products using its unique liposomal technologies. The company focuses on the development of novel pain-relief treatments for the treatment of osteoarthritis. Moebius Medical was founded in the year 2008 and has its headquarters in Tel Aviv, Israel. MARKET POTENTIAL AND POSITIONING The market outlook for MM-II, a novel non-opioid treatment for advanced osteoarthritis, especially osteoarthritis of the knee, developed by Sun Pharma and Moebius Medical, looks highly promising. With the increasing prevalence of osteoarthritis, especially among aging populations, there is a growing demand for innovative treatments. MM-II employs a proprietary suspension of large, empty multilamellar liposomes to reduce joint friction and wear, providing effective pain relief and potentially altering the progression of the disease. Recent data from the Phase II clinical trial, presented at EULAR 2024, demonstrated that patients with symptomatic knee osteoarthritis achieved significant and sustained pain relief for up to 26 weeks after receiving a 3mL dose of MM-II. This positions MM-II as a potentially superior option in the osteoarthritis therapeutics market, particularly for patients seeking long-term relief without relying on non-steroidal anti-inflammatory drugs (NSAIDs), which, while commonly used in osteoarthritis treatment, carry their risks. The robust clinical data also bolster the use of MM-II in therapy for osteoarthritis, highlighting its potential to reduce the need for frequent administrations. This could provide greater convenience for patients and cost savings for healthcare systems. As MM-II advances to Phase III trials and Sun Pharma pursues CE Mark approval in the European Union, the drug is anticipated to gain considerable traction in the arthritis market. Additionally, MM-II’s innovative approach has the potential to complement current osteoarthritis rehabilitation strategies, especially for knee osteoarthritis, and enhance the overall therapeutic landscape. The application of biomarkers in ongoing research may further refine patient selection and optimize treatment outcomes. REGIONAL ANALYSIS Inkwood Research offers an analysis of seven key markets: • United States o According to a study on symptomatic knee osteoarthritis by the American College of Rheumatology, around 14 million people in the United States are affected by symptomatic knee osteoarthritis (OA), with advanced OA representing more than half of these cases. o Notably, over half of those with symptomatic knee OA are under the age of 65. o Additionally, a considerable number of individuals with diagnosed symptomatic knee OA have experienced enough disease progression to qualify for knee replacement surgery if their symptoms are severe. • Germany • France • United Kingdom • Italy • Spain • Japan Table of ContentsTABLE OF CONTENTS1. INTRODUCTION TO THE REPORT 2. MM-II OVERVIEW 2.1. PRODUCT DETAIL 2.2. CLINICAL DEVELOPMENT 2.2.1. CLINICAL STUDIES 2.2.2. CLINICAL TRIALS INFORMATION 2.2.3. SAFETY AND EFFICACY 2.3. OTHER DEVELOPMENTAL ACTIVITIES 2.4. PRODUCT PROFILE 3. COMPETITIVE LANDSCAPE 3.1. MARKETED THERAPIES 3.2. LATE-STAGE EMERGING THERAPIES 4. MM-II MARKET ASSESSMENT 4.1. MARKET OUTLOOK OF MM-II IN OSTEOARTHRITIS 5. 7 MAJOR MARKET’S ANALYSIS 5.1. MARKET SIZE OF MM-II IN THE 7 MAJOR MARKETS FOR OSTEOARTHRITIS 5.2. 7 COUNTRY ANALYSIS 5.2.1. MARKET SIZE OF MM-II IN UNITED STATES FOR OSTEOARTHRITIS 5.2.2. MARKET SIZE OF MM-II IN GERMANY FOR OSTEOARTHRITIS 5.2.3. MARKET SIZE OF MM-II IN FRANCE FOR OSTEOARTHRITIS 5.2.4. MARKET SIZE OF MM-II IN ITALY FOR OSTEOARTHRITIS 5.2.5. MARKET SIZE OF MM-II IN SPAIN FOR OSTEOARTHRITIS 5.2.6. MARKET SIZE OF MM-II IN UNITED KINGDOM FOR OSTEOARTHRITIS 5.2.7. MARKET SIZE OF MM-II IN JAPAN FOR OSTEOARTHRITIS 6. SWOT ANALYSIS 7. ANALYST PERSPECTIVE
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(その他)の最新刊レポート
Inkwood Research 社の最新刊レポート本レポートと同じKEY WORD(pipeline)の最新刊レポート
よくあるご質問Inkwood Research社はどのような調査会社ですか?Inkwood Researchは世界40ヶ国以上の国を対象に広範な市場を調査し、世界市場全体を調査したレポートに加え、アジア太平洋地域、欧州、北米などの主要地域や主要国毎のレポートも数多く出版してい... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/09/24 10:26 144.74 円 161.12 円 195.86 円 |